Namir Hassan

Namir Hassan serves as CEO of Zelluna Immunotherapy. He has over 15 years of biotech and pharma industry experience spanning from target validation through to early phase clinical trials and has mostly focussed on Oncology and the development of TCR based immunotherapies. Prior to joining Zelluna, Namir was VP at Immunocore responsible for building and overseeing research biology and translational science for the Oncology pipeline then building a unit focussed on deployment of the platform in infectious diseases.

Previously, Namir had a leadership role in the discovery research organization within GSK and has worked at the Ludwig Institute for Cancer Research. Namir received a DPhil from the University of Oxford in T-cell Biology.